Evaluation of antibody persistence in Ghanaian children more than five years after vaccination with MenAfriVac® widely used in Sub-Saharan Africa to prevent epidemic Meningitis

Not Applicable

Completed

• Conditions: Meningococcal A disease; Nervous System Diseases

• Registration Number: ISRCTN10763234
• Lead Sponsor: Program for Appropriate Technology in Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-29
• Study Completion: 2017-12-31
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1028

Inclusion Criteria

1. Enrolled in the initial study intervention group and completed the final blood draw at 36 weeks
OR
2. Received at age 12-18 months (inclusive) a single dose of MenAfriVac® during the national campaign in 2012 (new control group)

Exclusion Criteria

1. Any chronic condition or medical/hereditary history suggesting subject would be immuno-compromised (i.e. HIV, autoimmune disease)
2. Non-residence in the study area or intent to move out within one year (new control group only)
3. Any condition or criteria that in the opinion of the investigator might compromise the well-being of the subject or the compliance with study procedures or interfere with the outcome of the study

Study & Design

• Study Type: Observational
• Study Design: Not specified